MAPT and Alzheimer disease: By delivering therapeutic payloads precisely to diseased tissues while mitigating off-target effects, QDs present a promising avenue for traversing the blood-brain barrier (BBB) and selectively targeting pathological hallmarks of AD, such as Aβ plaques and tau aggregates [12].